Skip to content
Screener

Zymeworks ZYME Royalties — Research and development collaborations

Other product segments

Other drug supply
$1.66M
Drug supply for ongoing studies
$791K
Development support payments
$291K
Milestone revenue
$0
Option exercise fee
$0
Recognition of deferred revenue
$0

Similar metrics at other companies

BioCryst Pharmaceuticals logo
BCRXResearch and Development — Collaboration revenue
$1.22M
Kopin logo
KOPNResearch And Development — Revenue
$1.29M+4.3%
SIGA Technologies logo
SIGAResearch And Development — Revenue
$3.13M+57.0%
Flexible Solutions International logo
FSIResearch And Development Sales — Revenue
$625K
Sutro Biopharma logo
STROResearch And Development Services — Revenue
$556K-38.1%
Kopin logo
KOPNResearch And Development Revenues — Revenue
$1.29M+4.3%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.7B+83.2%
Enterprise value$1.54B+81.1%
P/S45.8×+38.3×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Development support payments$291$475$683$4,968
Drug supply for ongoing studies7911,8411,1364,798
Other drug supply451622,150
Royalties1,5895502,919752
BeOne:
Milestone revenue20,00020,000
Recognition of deferred revenue18,33418,334
Drug supply1,66471,664215

Item 1. Financial Statements

FAQ

What is Zymeworks's royalties — research and development collaborations?
Zymeworks (ZYME) reported royalties — research and development collaborations of $1.59M in Q2 2026.
How has Zymeworks's royalties — research and development collaborations changed year-over-year?
Zymeworks's royalties — research and development collaborations increased by 188.9% year-over-year, from $550K to $1.59M.
What does royalties — research and development collaborations mean?
This metric represents revenue recognized from research and development collaboration agreements within the royalties segment. It reflects the financial value generated through partnerships where the company provides its proprietary technology platforms or expertise to external entities for drug discovery and development. This serves as an indicator of the company's ability to monetize its intellectual property and scientific capabilities through strategic alliances.

Ask your AI about Zymeworks's royalties — research and development collaborations.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude